

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT

“LORNOXICAM FOR INJECTION” APPROVED FOR MARKETING

The board (the “**Board**”) of directors (the “**Directors**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Lornoxicam for Injection (注射用氯諾昔康)” developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Company, has obtained the approval for marketing from the National Medical Products Administration of the PRC (國家藥品監督管理局) for the short-term treatment of moderate acute post-operative pain.

Lornoxicam being a thienothiazine derivative, is a non-steriodal drug that possesses potent analgesic and anti-inflammatory effects. It is used to relieve various types of pain arising from multiple causes, and is primarily used in relieving moderate acute post-operative pain following surgery, as well as symptoms of acute lumbar and sciatica pains. Surgically, it is used in combination with other drugs throughout the perioperative period, and is a preferred choice for multimodal analgesia (balanced analgesia) approach.

Lornoxicam delivers anti-inflammatory and analgesic effects, and blocks pain signal transmission by inhibiting Cyclooxygenase activity, thereby reducing prostaglandin synthesis. Lornoxicam can also produce a central analgesic effect by activating the opioid neuropeptide system, further enhancing its analgesic efficacy. As an analgesic drug, Lornoxicam exhibits a lower risk of causing respiratory depression and addiction risks associated with opioids. Its post-operative analgesic efficacy is comparable to that of morphine, but generates fewer adverse reactions such as nausea and vomiting.

“Lornoxicam for Injection” is a Class B drug under the National Healthcare Security Administration of the PRC (國家醫療保障局). It is recommended by authoritative guidelines in the PRC, including the *Expert Consensus on Early Analgesia for Non-traumatic Acute Abdomen in Adults*, the *Expert Consensus on Postoperative Pain Management in Adults*, and the *Guidelines for Anesthesia in Day-case Surgery*, and is characterized as a “rapid analgesia with potent efficacy and safety”. According to data from Menet, the sales revenue of Lornoxicam for Injection across the three major terminals and six major markets in the PRC exceeded RMB300 million in aggregate in 2025.

“Lornoxicam for Injection” is another important product of the Group, which further enriches the Company’s anti-inflammatory and analgesic product pipeline and will provide more therapeutic options for a wide range of patients.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 11 May 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

** for identification purpose only*